Drug Insights

Is Idecabtagene vicleucel approved by the FDA?

10 July 2024
3 min read

Idecabtagene vicleucel, commonly known by its brand name Abecma, is a pioneering immunotherapy used in the treatment of multiple myeloma, a type of blood cancer. Abecma (idecabtagene vicleucel) received approval from the U.S. Food and Drug Administration (FDA) on March 26, 2021. This marked a significant advancement in cancer treatment, providing a new option for patients with relapsed or refractory multiple myeloma who have exhausted other treatments.

Mechanism of Action

Abecma is a type of CAR-T cell therapy. It is created using the patient’s own white blood cells, which are collected and genetically modified to express a receptor that targets and kills multiple myeloma cells. This personalized treatment involves several steps:

  1. Leukapheresis: Collection of white blood cells from the patient.
  2. Genetic Modification: The cells are engineered in a lab to produce chimeric antigen receptors (CARs).
  3. Expansion: The modified cells are multiplied.
  4. Infusion: After preparatory chemotherapy, the CAR-T cells are infused back into the patient.

Usage and Administration

Idecabtagene vicleucel is administered in a specialized medical setting due to its complexity and the potential for severe side effects. The process includes:

  1. Pre-treatment with Chemotherapy: Given to prepare the body for the CAR-T cell infusion.
  2. Infusion: The modified cells are infused intravenously.
  3. Monitoring: Patients are closely monitored for at least seven days post-infusion to manage any immediate adverse reactions.

Side Effects and Warnings

Common Side Effects:

  • Cytokine release syndrome (CRS): Symptoms include fever, chills, difficulty breathing, and rapid heartbeats.
  • Neurological toxicities: Issues like confusion, memory problems, and seizures.
  • Infections: Due to immunosuppression.
  • Low blood cell counts: Leading to symptoms like fatigue, increased infection risk, and easy bruising.

Severe Side Effects:

  • CRS: This is a potentially life-threatening condition that requires immediate medical intervention.
  • Neurological toxicities: Severe effects such as encephalopathy and seizures necessitate close monitoring.

Patients must remain near the treatment facility for at least four weeks after infusion to ensure any severe side effects can be promptly managed.

Precautions

Before starting idecabtagene vicleucel, it’s essential to inform the healthcare provider about:

  • Any active infections.
  • History of hepatitis B or cytomegalovirus.
  • Recent vaccinations (within the last six weeks).

Pregnancy and Breastfeeding:

  • Women may need to undergo pregnancy testing and use effective contraception during and shortly after treatment.
  • It may not be safe to breastfeed during treatment.

Lifestyle Considerations:

  • Avoid driving or operating heavy machinery for at least eight weeks post-treatment due to potential cognitive and motor impairments.
  • Refrain from receiving live vaccines and donating blood, organs, or tissues.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

SciRhom Raises EUR 63 Million in Series A to Boost iRhom2 Therapy for Autoimmune Diseases
Latest Hotspot
3 min read
SciRhom Raises EUR 63 Million in Series A to Boost iRhom2 Therapy for Autoimmune Diseases
10 July 2024
SciRhom GmbH has declared the successful conclusion of a EUR 63 million Series A funding round.
Read →
Is Azstarys approved by the FDA?
Drug Insights
3 min read
Is Azstarys approved by the FDA?
10 July 2024
Azstarys was approved by the U.S. Food and Drug Administration (FDA) on March 2, 2021.
Read →
GPCR Family Anticancer Targets and Marketed Therapeutic Drugs (Part 1)
Drug Highlight
7 min read
GPCR Family Anticancer Targets and Marketed Therapeutic Drugs (Part 1)
10 July 2024
This article will inventory the anti-tumor targets in the GPCR family and the therapeutic drugs that have been marketed.
Read →
Is Fosdenopterin approved by the FDA?
Drug Insights
3 min read
Is Fosdenopterin approved by the FDA?
10 July 2024
Fosdenopterin (Nulibry) was approved by the U.S. Food and Drug Administration (FDA) on February 26, 2021.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.